Two companies, Sai Parenteral Limited and Hella Infra Market, are set to launch their initial public offerings (IPOs) after receiving approval from SEBI.
Promoters to Sell Shares in Sai Parenteral IPO
Telangana-based Sai Parenteral Limited filed for an IPO on September 30, 2025. The IPO will include:
A fresh issue of shares worth ₹285 crore
An offer for sale of 3,500,000 shares by existing investors
Several existing shareholders, including Vikas India EIF-I, Tilokchand Punamchand Ostwal, Devendra Chawla, Bhanwar Lal Chandak, Srilekha, Padma, Vijay Gondi, and Idea & Journey Private Limited, plan to reduce their stakes through this IPO.
Hella Infra Market has applied to SEBI through a confidential route, so its IPO details have not been disclosed to the public yet.
How Sai Parenteral Plans to Use IPO Funds
Sai Parenteral Limited has outlined its plan for the proceeds from the IPO:
₹100 crore for expanding capacity and developing its manufacturing center
₹18 crore for research and development
₹20 crore to pay off current outstanding dues
₹33.30 crore for working capital needs
₹36 crore to invest in its subsidiaries
About Sai Parenteral Limited
Sai Parenteral is a pharmaceutical company focused on research, development, and manufacturing. It serves both domestic and international markets with:
Branded generic formulations
Contract development and manufacturing services
Its product range includes tablets, capsules, and other medicines for antibiotics, antidiabetics, vitamins, minerals, and dietary supplements.
